Websites, domains, hosts that links to azpicentral.com
Our database shows, that the website azpicentral.com is linked by a total of 32 websites.
Number of websites/domains displayed: 32
Results found: 32
Websites discovered:
TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) | HCP Sitehttp://pageoverview.com/website-report/tudorzahcp.com
Healthcare professional information on TUDORZA PRESSAIR (aclidinium bromide inhalation powder), an anticholinergic indicated for the long-term maintenance treatment of bronchospasm associated with COPD.
- Expected expiration: May 10th in 2020
- Creation date: May 10th in 2012
- Renew date: March 24th in 2016
ONGLYZA® (saxagliptin) | Adult Type 2 Diabetes Medicationhttp://pageoverview.com/website-report/onglyza.com
Read information about ONGLYZA® (saxagliptin), an adult type 2 diabetes medication used with diet and exercise to help reduce A1C levels.
- Expected expiration: January 19th in 2019
- Creation date: January 19th in 2006
- Renew date: January 15th in 2018
PI-Centralhttp://pageoverview.com/website-report/azpicentral.com
- Expected expiration: July 8th in 2017
- Creation date: July 8th in 2014
- Renew date: January 29th in 2016
MOVANTIK® (naloxegol) | Opioid Induced Constipation Treatmenthttp://pageoverview.com/website-report/movantik.com
Official Web site for MOVANTIK® (naloxegol) tablets, for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
- Expected expiration: September 25th in 2017
- Creation date: September 25th in 2013
- Renew date: September 20th in 2016
Acid Reflux Medication | NEXIUM® (esomeprazole magnesium)http://pageoverview.com/website-report/purplepill.com
Discover NEXIUM, the Purple Pill, which offers 24-hour heartburn relief caused by acid reflux disease. Ask your doctor if NEXIUM may be right for you.
- Expected expiration: October 29th in 2017
- Creation date: October 29th in 1999
- Renew date: October 25th in 2016
BRILINTA® (ticagrelor) tablets | Heart Attack Treatmenthttp://pageoverview.com/website-report/brilinta.com
Read about BRILINTA® (ticagrelor) tablets, a prescription medication for heart attack treatment, or severe chest pain, also known as unstable angina.
- Expected expiration: April 21st in 2018
- Creation date: April 21st in 2005
- Renew date: April 17th in 2017
BEVESPI AEROSPHERE® (glycopyrrolate/ formoterol fumarate) Inhalation Aerosolhttp://pageoverview.com/website-report/bevespiaerosphere.com
BEVESPI AEROSPHERE® (glycopyrrolate/ formoterol fumarate) is a long‐term, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.
- Expected expiration: August 13th in 2018
- Creation date: August 13th in 2015
- Renew date: August 9th in 2017
FARXIGA® (dapagliflozin) | Type 2 Diabetes Medication for Adultshttp://pageoverview.com/website-report/farxiga.com
FARXIGA® (dapagliflozin) is an adult type 2 diabetes medication used with diet and exercise to improve glycemic control.
- Expected expiration: August 27th in 2017
- Creation date: August 27th in 2013
- Renew date: August 23rd in 2016
P&T Community |http://pageoverview.com/website-report/ptcommunity.com
- Expected expiration: May 20th in 2017
- Creation date: May 20th in 2002
- Renew date: July 22nd in 2015
- Google Analytics: 2492160-1
MOVANTIK® (naloxegol) | Mu-Opioid Receptor Antagonisthttp://pageoverview.com/website-report/movantikhcp.com
Official health care professional Web site for MOVANTIK® (naloxegol) tablets, for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
- Expected expiration: February 14th in 2019
- Creation date: February 14th in 2014
- Renew date: January 29th in 2016
Bipolar Disorder Medication | SEROQUEL XR® (quetiapine fumarate)http://pageoverview.com/website-report/seroquelxr.com
Find information to better understand major depressive disorder (MDD), bipolar disorder, bipolar depression, and SEROQUEL XR® (quetiapine fumarate).
- Expected expiration: March 29th in 2018
- Creation date: March 29th in 2007
- Renew date: March 25th in 2017
FASENRA™ (benralizumab) Subcutaneous Injection 30 mghttp://pageoverview.com/website-report/fasenra.com
FASENRA™ (benralizumab) is a prescription medicine used with other asthma medicines for the maintenance treatment of asthma in adults whose asthma is not controlled with their current asthma medicines.
- Expected expiration: August 1st in 2018
- Creation date: August 1st in 2016
- Renew date: September 13th in 2017
PARP inhibitor for Advanced Ovarian Cancer | LYNPARZA® (olaparib)http://pageoverview.com/website-report/lynparzahcp.com
LYNPARZA® (olaparib) is the first and only PARP inhibitor approved in 2 distinct settings: maintenance for recurrent ovarian cancer and following 3 or more lines of prior chemotherapy.
- Expected expiration: December 4th in 2018
- Creation date: December 4th in 2014
- Renew date: November 30th in 2017
SYNAGIS® (palivizumab) Parent & Caregiver Websitehttp://pageoverview.com/website-report/synagis.com
Parent and caregiver information for SYNAGIS, a therapy to help prevent a serious lung disease caused by respiratory syncytial virus (RSV) in children at high risk for severe lung disease from RSV.
- Expected expiration: September 8th in 2018
- Creation date: September 9th in 1998
- Renew date: September 4th in 2017
LYNPARZA® (olaparib) | Ovarian Cancer Treatmenthttp://pageoverview.com/website-report/lynparza.com
LYNPARZA®(olaparib) is a type of targeted therapy for ovarian cancer called a PARP inhibitor. LYNPARZA may be used at different stages of ovarian cancer treatment.
- Expected expiration: February 10th in 2019
- Creation date: February 10th in 2014
- Renew date: January 29th in 2016
FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) | Flu Vaccinehttp://pageoverview.com/website-report/flumistquadrivalent.com
Help protect against seasonal flu with FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) - the flu vaccine that starts working in the nose.
- Expected expiration: December 6th in 2017
- Creation date: December 6th in 2011
- Renew date: December 2nd in 2016
FARXIGA® (dapagliflozin) | Treatment for Type 2 Diabetes Mellitus in Adultshttp://pageoverview.com/website-report/farxiga-hcp.com
FARXIGA® (dapagliflozin) is an SGLT2 inhibitor indicated for patients with type 2 diabetes mellitus. Explore the science behind FARXIGA.
- Expected expiration: September 23rd in 2017
- Creation date: September 23rd in 2013
- Renew date: September 19th in 2016
IRESSA® (gefitinib) Treatmenthttp://pageoverview.com/website-report/iressa-usa.com
IRESSA® (gefitinib) is a treatment for patients.
- Expected expiration: June 8th in 2018
- Creation date: June 8th in 2015
- Renew date: June 4th in 2017